logo
logo

Preventice Solutions Announces $137 Million Series B Financing Led by Vivo Capital

Jul 15, 2020•almost 5 years ago

Amount Raised

$137 Million

Round Type

series b

Minneapolis

Description

 Preventice Solutions, a leader in digital healthcare solutions and remote cardiac monitoring services powered by deep learning and artificial intelligence (AI), today announced that it has raised $137M in a Series B financing to accelerate investment in salesforce expansion, technology and product innovation and further development of clinical evidence supporting its flagship solution. The financing was led by new investor, Vivo Capital, with participation by another new investor, Novo Holdings A/S, as well as significant support from existing investors, including Merck Global Health Innovation Fund, Boston Scientific and Samsung Catalyst Fund.

Company Information

Company

Vivo Capital

Location

Minneapolis, Minnesota, United States

About

Founded in 1996, Vivo Capital is a global investment firm focused on healthcare. Vivo has approximately $4.3 billion in assets under management, invested in over 260 public and private companies worldwide. The firm is headquartered in Palo Alto, California, with additional offices in Asia. The Vivo team consists of more than 50 multi-disciplinary professionals, including, physicians, scientists, entrepreneurs, operating executives, and industry experts. Vivo provides a multi-fund investment platform, covering growth equity, private equity including buyout, venture capital, and public equity. Across all fund strategies, Vivo invests broadly in the healthcare sector including biotechnology, pharmaceuticals, medical devices, and healthcare services.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech